Detail akcie CEL-SCI Rg online

Business Summary: CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
Financial Summary: BRIEF: For the three months ended 31 December 2023, CEL-SCI Corp revenues was not reported. Net loss applicable to common stockholders decreased 16% to $6.7M. Lower net loss reflects $445,710, $438,738 and $434,030 respecti decrease of 19% to $4.4M (expense), General & administrative decrease of 6% to $2.1M (expense), Int exp on Financial Lease liab. decrease of 33% to $200K (expense).